<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03265808</url>
  </required_header>
  <id_info>
    <org_study_id>20170674</org_study_id>
    <secondary_id>1R01AA024933-01A1</secondary_id>
    <nct_id>NCT03265808</nct_id>
  </id_info>
  <brief_title>Allogeneic HUman Mesenchymal Stem Cell InfusioN Versus Placebo in Subjects With Alcohol Use Disorder and Major DepreSsion.</brief_title>
  <acronym>Alaunus</acronym>
  <official_title>A Phase I/II, Prospective, Randomized, Double-Blind, PlAcebo-ControLled Trial to EvAluate the Potential Efficacy of Allogeneic HUman Mesenchymal Stem Cell InfusioN Versus Placebo in Subjects With Alcohol Use Disorder and Major DepreSsion.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joshua M Hare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at the safety of a study treatment with stem cells in
      Alcohol Use Disorder And Major Depression (AUD-MD) subjects.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 18, 2018</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incident of treatment emergent-serious adverse events</measure>
    <time_frame>One month post-infusion</time_frame>
    <description>Incidence of any treatment-emergent serious adverse events, defined as a composite of acute suicidality and hospitalization for suicide attempts.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in serum concentrations of high sensitivity C-reactive protein.</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Change in serum concentrations of high sensitivity C-reactive protein. A serum sample will be collected to assess the change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum concentrations of inflammatory biomarkers</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Change in serum concentrations of inflammatory biomarkers, such as in TNF alpha and interleukin-6. A serum sample will be collected to assess the change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in depressive symptoms as assessed by MADRS</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Montgomery and Asberg Depression Rating Scale (MADRS) is a ten item questionnaire with a total score ranging from 0-60 with a higher score indicating higher depressive symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Depressive symptoms as assessed by CGI</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Clinical Global Improvement (CGI) is rated on a 7 point scale ranging from 1 (very much improved) to 7 (very much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quantity of alcohol use as assessed by TLFB</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>30-day self report Timeline Follow Back (TLFB) questionnaire will be used to assess daily alcohol use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in frequency of alcohol use as assessed by TLFB</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>30-day self report Timeline Follow Back (TLFB) questionnaire will be used to assess frequency of daily alcohol use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Anhedonia as measured by SHAPS</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Snaith Hamilton Pleasure Scale (SHAPS) is a 14 item questionnaire with a total score ranging from 0-56 with a higher score indicating increased anhedonic symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cravings as assessed by AUQ</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Alcohol Urge Questionnaire (AUQ) is an 8 item questionnaire with total score ranging from 8-56 with a high score indicating increased cravings .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cravings as assessed by OCDS</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Obsessive-Compulsive Drinking Scale (OCDS) is a 14 item questionnaire ranging from 0-56 with a higher score indicating increase cravings.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognition as assessed by BAC-A</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Brief Assessment of Cognition for Affective Disorders (BAC-A) includes brief assessments of executive functions, verbal fluency, attention, verbal memory, working memory and motor speed. Z-scores are calculated from composite scores. Higher z-scores are indicative of better cognitive performance, lower z-scores are indicative of lower cognitive performance. Range of z-scores anticipated to be between -3 and 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in functioning as assessed by UPSA-B</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>University of California of San Diego (UCSD) Performance Based Skills Assessment (UPSA-B) questionnaire has a total score from 0-100 with a higher score indication better functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in functioning as assessed by GAF</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Global Assessment of Functioning (GAF) questionnaire has a total score ranging from 1-100 with a higher score indicating of daily activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life as assessed by QOLI</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Quality of Life Index (QOLI) questionnaire has a total score ranging from 10-100 with a higher score indicating higher quality of life.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>allogeneic human mesenchymal stem cells (allo-hMSCs)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be treated with a single administration of allogeneic hMSCs: 100 x 10^6 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be treated with a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>allogeneic human mesenchymal stem cells (allo-hMSCs)</intervention_name>
    <description>Single administration of allogeneic hMSCs: 100 x 106 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.</description>
    <arm_group_label>allogeneic human mesenchymal stem cells (allo-hMSCs)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provide written informed consent.

          2. Subjects age &gt;18 and &lt;75 years at the time of signing the Informed Consent Form.

          3. Diagnostic and Statistical Manual of Mental Disorder-5 criteria for Alcohol Urge
             Questionnaire (moderate or severe defined as meeting 4 or more of the 11 criteria) AND
             a concurrent Diagnostic and Statistical Manual of Mental Disorder-5 recurrent unipolar
             major depression with HRSD-25 score of 18 or above.

          4. A history of a depressive episode occurring or persisting during a period of one-month
             abstinence.

          5. Participants should express the desire to reduce or stop alcohol consumption, report
             28 or more standard drinks (SD) per week for males or 21 for females over four weeks
             during the 90 days preceding study enrollment.

          6. Increased inflammation ([serum C-reactive protein] ≥3.0 mg/L.

          7. Agree to taper and discontinue antidepressant medications during the 12-week trial.

          8. Able to provide informed consent and comply with study procedures.

          9. Able to read English and understand study instruments.

         10. Entry criteria for depression and alcohol use disorder (moderate or severe) will be
             established using the Structured Clinical Interview for Diagnostic and Statistical
             Manual of Mental Disorders (SCID) for categorical diagnosis.

         11. Have a score of ≥18 on the Hamilton Depression Rating Scale for Depression (HAM-D).

        Exclusion Criteria:

          1. Acute suicidality.

          2. Any lifetime history of bipolar disorder, schizophrenia, or schizoaffective disorder.

          3. Active psychotic disorder, eating disorder, or substance use disorder except for
             alcohol and tobacco or &quot;mild&quot; cannabis use disorder within 6 months of enrollment.

          4. Any lifetime history of autoimmune or immunodeficiency syndrome.

          5. Treatment with any psychotropic (including hypnotic), steroidal, or anti-inflammatory
             medication (including NSAIDs) within 2 weeks of treatment randomization (6 weeks for
             fluoxetine).

          6. Any current use of medication that affect alcohol consumption such as acamprosate,
             disulfiram, naltrexone (po or IM), topiramate, or sedative-hypnotics including
             benzodiazepines or any psychostimulant.

          7. Being enrolled in an alcohol treatment program (self-help groups participation such as
             Alcoholics Anonymous or Dual Diagnosis self-help are allowed).

          8. Active medical condition that could cause or exacerbate depressive symptoms (e.g.,
             hypothyroidism, anemia).

          9. Currently pregnant or breast-feeding.

         10. Lack of use of a reliable means of contraception methods. (Female subjects of
             childbearing potential must undergo a serum or urine pregnancy test at screening and
             within 36 hours prior to infusion.)

         11. First major depressive episode after 50 years of age.

         12. Any evidence of current infection including serum positive for HIV, hepatitis BsAg or
             Viremic hepatitis.

         13. Medical conditions with known autoimmune or inflammatory mechanisms including any
             chronic allergic condition.

         14. Positive urine screens for any drug of abuse other than cannabis at baseline.

         15. Inability to read or understand study forms or informed consent or the presence of any
             other conditions or factors, which in the opinion of the investigator would make the
             patient unsuitable for study participation.

         16. Prior history of a suicide attempt, within the past year.

         17. Have hypersensitivity to dimethyl sulfoxide (DMSO).

         18. Have a clinical history of malignancy within 3 years (i.e., subjects with prior
             malignancy must be disease free for 3 years), except curatively-treated basal cell
             carcinoma, squamous cell carcinoma, melanoma in situ or cervical carcinoma.

         19. Be serum positive for HIV, hepatitis BsAg or Viremic hepatitis C.

         20. Be currently participating (or participated within the previous 30 days) in an
             investigational therapeutic or device trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dante M Durand, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://isci.med.miami.edu</url>
    <description>ISCI Study website</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 16, 2017</study_first_submitted>
  <study_first_submitted_qc>August 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2017</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Joshua M Hare</investigator_full_name>
    <investigator_title>Sponsor</investigator_title>
  </responsible_party>
  <keyword>stem cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Alcoholism</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

